Abstract
Peptide vaccines represent a potential strategy for the prevention and treatment of pathogenic diseases, cancers and autoimmune disorders; their low cost, ease of synthesis and inherent safety are all attractive features. However, they have remained largely unsuccessful owing to low immunogenicity, predominantly stemming from reduced bioavailability due to rapid proteolytic degradation in vivo. The field of peptidomimetics, through chemical alteration of epitope structure, attempts to modify peptides to engender improved immunogenicity and stability, with the ultimate aim of rationally designing more efficacious vaccines. This article discusses the strategies employed in this process and recent advances within the field.
Acknowledgements
The authors wish to thank Nadine L Dudek for helpful critical review of this manuscript.
Financial & competing interests disclosure
Anthony W Purcell is a National Health and Medical Research Council of Australia Senior Research Fellow. The financial support of the Australian Research Council (Linkage project LP0883541), National Health and Medical Research Council of Australia (project grants 508927 and 508929) is gratefully acknowledged. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.